Advances with lipid-lowering drugs for pediatric patients with familial hypercholesterolemia

References

• Defesche JC, Gidding SS, Harada-Shiba M, et al. Familial hypercholesterolaemia. Nat Rev Dis Primers. 2017;3:17093.
   PubMed Web of Science ®Google Scholar
• Sturm AC, Knowles JW, Gidding SS, et al. Clinical genetic testing for familial hypercholesterolemia: JACC scientific expert panel. J Am Coll Cardiol. 2018;72(6):662–680.
   PubMed Web of Science ®Google Scholar
• Nordestgaard BG, Chapman MJ, Humphries SE, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013;34(45):3478–90a.
   PubMed Web of Science ®Google Scholar
• Wiegman A, Gidding SS, Watts GF, et al. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J. 2015;36(36):2425–2437.
   PubMed Web of Science ®Google Scholar
• Wong B, Kruse G, Kutikova L, et al. Cardiovascular disease risk associated with familial hypercholesterolemia: a systematic review of the literature. Clin Ther. 2016;38(7):1696–1709.
   PubMed Web of Science ®Google Scholar
• Masana L, Zamora A, Plana N, et al. Incidence of cardiovascular disease in patients with familial hypercholesterolemia phenotype: analysis of 5 years follow-up of real-world data from more than 1.5 million patients. J Clin Med. 2019;8(7):1080.
   Web of Science ®Google Scholar
• Willemon KA, Patel J, Aguilar-Salinas C, et al. Reducing the clinical and public health burden of familial hypercholesterolemia: a global call to action. JAMA Cardiol 2020;5(2):217–229.
   PubMed Web of Science ®Google Scholar
• Santos RD, Stein EA, Hovingh GK, et al. Long-term evolocumab in patients with familial hypercholesterolemia. J Am Coll Cardiol. 2020;75(6):565–574.
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Laufs U, Ray KK, et al. Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy. Eur J Prev Cardiol. 2020;27(6):593–603.
   PubMed Web of Science ®Google Scholar
• Ben-Omran T, Masana L, Kolovou G, et al. Real-world outcomes with lomitapide use in paediatric patients with homozygous familial hypercholesterolaemia. Adv Ther. 2019;36(7):1786–1811.
   PubMed Web of Science ®Google Scholar
• de Ferranti SD, Steinberger J, Ameduri R, et al. Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association. Circulation. 2019;139(13):e603–e34.
   PubMed Web of Science ®Google Scholar
• Cuchel M, Bruckert E, Ginsberg HN, et al. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the consensus panel on familial hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J. 2014;35(32):2146–2157.
   PubMed Web of Science ®Google Scholar
• Beheshti SO, Madsen CM, Varbo A, et al. Worldwide prevalence of familial hypercholesterolemia: meta-analyses of 11 million subjects. J Am Coll Cardiol. 2020;75(20):2553–2566.
   PubMed Web of Science ®Google Scholar
• Hu P, Dharmayat KI, Stevens CAT, et al. Prevalence of familial hypercholesterolemia among the general population and patients with atherosclerotic cardiovascular disease: a systematic review and meta-analysis. Circulation. 2020;141(22):1742–1759.
   PubMed Web of Science ®Google Scholar
• Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. J Am Coll Cardiol. 2019;73(24):e285–e350.
   PubMed Web of Science ®Google Scholar
• Goldberg AC, Hopkins PN, Toth PP, et al. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the national lipid association expert panel on familial hypercholesterolemia. J Clin Lipidol. 2011;5(3 Suppl):S1–8.
   PubMedGoogle Scholar
• Ramaswami U, Futema M, Bogsrud MP, et al. Comparison of the characteristics at diagnosis and treatment of children with heterozygous familial hypercholesterolaemia (FH) from eight European countries. Atherosclerosis. 2020;292:178–187.
   PubMed Web of Science ®Google Scholar
• Neil HA, Hammond T, Huxley R, et al. Extent of underdiagnosis of familial hypercholesterolaemia in routine practice: prospective registry study. BMJ (Clin Res Ed). 2000;321(7254):148.
   PubMedGoogle Scholar
• Familial hypercholesterolaemia: identification and management. Clinical guideline [CG71]. Published date: 27 August 2008. Last updated: 04 October 2019 Available from: https://www.nice.org.uk/guidance/CG71.
   Google Scholar
• Williams RR, Hunt SC, Schumacher MC, et al. Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. Am J Cardiol. 1993;72(2):171–176.
   PubMed Web of Science ®Google Scholar
• Watts GF, Gidding S, Wierzbicki AS, et al. Integrated guidance on the care of familial hypercholesterolemia from the International FH Foundation. J Clin Lipidol. 2014;8(2):148–172.
   PubMed Web of Science ®Google Scholar
• Santos RD, Gidding SS, Hegele RA, et al. Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the international atherosclerosis society severe familial hypercholesterolemia panel. Lancet Diabetes Endocrinol. 2016;4(10):850–861.
   PubMed Web of Science ®Google Scholar
• Raal FJ, Santos RD. Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment. Atherosclerosis. 2012;223(2):262–268.
   PubMed Web of Science ®Google Scholar
• Benn M, Watts GF, Tybjaerg-Hansen A, et al. Familial hypercholesterolemia in the danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication. J Clin Endocrinol Metab. 2012;97(11):3956–3964.
   PubMed Web of Science ®Google Scholar
• Mundal LJ, Igland J, Veierod MB, et al. Impact of age on excess risk of coronary heart disease in patients with familial hypercholesterolaemia. Heart. 2018;104(19):1600–1607.
   PubMed Web of Science ®Google Scholar
• Khera AV, Won HH, Peloso GM, et al. Diagnostic yield and clinical utility of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia. J Am Coll Cardiol. 2016;67(22):2578–2589.
   PubMed Web of Science ®Google Scholar
• Wiegman A, de Groot E, Hutten BA, et al. Arterial intima-media thickness in children heterozygous for familial hypercholesterolaemia. Lancet. 2004;363(9406):369–370.
   PubMed Web of Science ®Google Scholar
• Wiegman A, Hutten BA, de Groot E, et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. Jama. 2004;292(3):331–337.
   PubMed Web of Science ®Google Scholar
• Gidding SS, Bookstein LC, Chomka EV. Usefulness of electron beam tomography in adolescents and young adults with heterozygous familial hypercholesterolemia. Circulation. 1998;98(23):2580–2583.
   PubMed Web of Science ®Google Scholar
• Gidding SS, Champagne MA, de Ferranti SD, et al. The agenda for familial hypercholesterolemia: a scientific statement from the American Heart Association. Circulation. 2015;132(22):2167–2192.
   PubMed Web of Science ®Google Scholar
• Sirtori CR. The pharmacology of statins. Pharmacol Res. 2014;88:3–11.
   PubMed Web of Science ®Google Scholar
• Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;388(10059):2532–2561.
   PubMed Web of Science ®Google Scholar
• Vuorio A, Kuoppala J, Kovanen PT, et al. Statins for children with familial hypercholesterolemia. Cochrane Database Syst Rev. 2019;2019(11):CD006401.
   PubMed Web of Science ®Google Scholar
• Anagnostis P, Vaitsi K, Kleitsioti P, et al. Efficacy and safety of statin use in children and adolescents with familial hypercholesterolaemia: a systematic review and meta-analysis of randomized-controlled trials. Endocrine. 2020;69(2):249–261.
   PubMed Web of Science ®Google Scholar
• Versmissen J, Oosterveer DM, Yazdanpanah M, et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ (Clin Res Ed). 2008;337:a2423.
   PubMed Web of Science ®Google Scholar
• Besseling J, Hovingh GK, Huijgen R, et al. Statins in familial hypercholesterolemia: consequences for coronary artery disease and all-cause mortality. J Am Coll Cardiol. 2016;68(3):252–260.
   PubMed Web of Science ®Google Scholar
• Luirink IK, Wiegman A, Kusters DM, et al. 20-year follow-up of statins in children with familial hypercholesterolemia. N Engl J Med. 2019;381(16):1547–1556.
   PubMed Web of Science ®Google Scholar
• Lambert M, Lupien PJ, Gagne C, et al. Treatment of familial hypercholesterolemia in children and adolescents: effect of lovastatin. Canadian lovastatin in children study group. Pediatrics. 1996;97(5):619–628.
   PubMed Web of Science ®Google Scholar
• Stein EA, Illingworth DR, Kwiterovich PO Jr., et al. Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: a randomized controlled trial. Jama. 1999;281(2):137–144.
   PubMed Web of Science ®Google Scholar
• Knipscheer HC, Boelen CC, Kastelein JJ, et al. Short-term efficacy and safety of pravastatin in 72 children with familial hypercholesterolemia. Pediatr Res. 1996;39(5):867–871.
   PubMed Web of Science ®Google Scholar
• van der Graaf A, Nierman MC, Firth JC, et al. Efficacy and safety of fluvastatin in children and adolescents with heterozygous familial hypercholesterolaemia. Acta Paediatr. 2006;95(11):1461–1466.
   PubMed Web of Science ®Google Scholar
• Gandelman K, Glue P, Laskey R, et al. An eight-week trial investigating the efficacy and tolerability of atorvastatin for children and adolescents with heterozygous familial hypercholesterolemia. Pediatr Cardiol. 2011;32(4):433–441.
   PubMed Web of Science ®Google Scholar
• McCrindle BW, Ose L, Marais AD. Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: a multicenter, randomized, placebo-controlled trial. J Pediatr. 2003;143(1):74–80.
   PubMed Web of Science ®Google Scholar
• Clauss SB, Holmes KW, Hopkins P, et al. Efficacy and safety of lovastatin therapy in adolescent girls with heterozygous familial hypercholesterolemia. Pediatrics. 2005;116(3):682–688.
   PubMed Web of Science ®Google Scholar
• Kusters DM, Avis HJ, de Groot E, et al. Ten-year follow-up after initiation of statin therapy in children with familial hypercholesterolemia. Jama. 2014;312(10):1055–1057.
   PubMed Web of Science ®Google Scholar
• Mamann N, Lemale J, Karsenty A, et al. Intermediate-term efficacy and tolerance of statins in children. J Pediatr. 2019;210:161–165.
   PubMed Web of Science ®Google Scholar
• de Jongh S, Ose L, Szamosi T, et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized, double-blind, placebo-controlled trial with simvastatin. Circulation. 2002;106(17):2231–2237.
   PubMed Web of Science ®Google Scholar
• Stein EA, Dann EJ, Wiegman A, et al. Efficacy of rosuvastatin in children with homozygous familial hypercholesterolemia and association with underlying genetic mutations. J Am Coll Cardiol. 2017;70(9):1162–1170.
   PubMed Web of Science ®Google Scholar
• Raal FJ, Pilcher GJ, Panz VR, et al. Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy. Circulation. 2011;124(20):2202–2207.
   PubMed Web of Science ®Google Scholar
• Eiland LS, Luttrell PK. Use of statins for dyslipidemia in the pediatric population. J Pediatr Pharmacol Ther. 2010;15(3):160–172.
   PubMedGoogle Scholar
• Ramaswami U, Humphries SE, Priestley-Barnham L, et al. Current management of children and young people with heterozygous familial hypercholesterolaemia - HEART UK statement of care. Atherosclerosis. 2019;290:1–8.
   PubMed Web of Science ®Google Scholar
• Avis HJ, Hutten BA, Gagne C, et al. Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia. J Am Coll Cardiol. 2010;55(11):1121–1126.
   PubMed Web of Science ®Google Scholar
• Braamskamp MJ, Stefanutti C, Langslet G, et al. Efficacy and safety of pitavastatin in children and adolescents at high future cardiovascular risk. J Pediatr. 2015;167(2):338–343. e5.
   PubMed Web of Science ®Google Scholar
• Bogsrud MP, Langslet G, Wium C, et al. Treatment goal attainment in children with familial hypercholesterolemia: A cohort study of 302 children in Norway. J Clin Lipidol. 2018;12(2):375–382.
   PubMed Web of Science ®Google Scholar
• Braamskamp MJ, Langslet G, McCrindle BW, et al. Effect of rosuvastatin on carotid intima-media thickness in children with heterozygous familial hypercholesterolemia: the CHARON study. Circulation. 2017;136(4):359–366.
   PubMed Web of Science ®Google Scholar
• Rodenburg J, Vissers MN, Wiegman A, et al. Statin treatment in children with familial hypercholesterolemia: the younger, the better. Circulation. 2007;116(6):664–668.
   PubMed Web of Science ®Google Scholar
• Gomes HA, Garcia P, Diogo L, et al. Experience on statin therapy in paediatric age: retrospective study in a Portuguese referral centre. Cardiol Young. 2020;30(6):840–851.
   PubMed Web of Science ®Google Scholar
• Daniels SR, Greer FR. Committee on N. Lipid screening and cardiovascular health in childhood. Pediatrics. 2008;122(1):198–208.
   PubMed Web of Science ®Google Scholar
• Harada-Shiba M, Ohta T, Ohtake A, et al. Guidance for pediatric familial hypercholesterolemia 2017. J Atheroscler Thromb. 2018;25(6):539–553.
   PubMed Web of Science ®Google Scholar
• Couture P, Brun LD, Szots F, et al. Association of specific LDL receptor gene mutations with differential plasma lipoprotein response to simvastatin in young French Canadians with heterozygous familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 1998;18(6):1007–1012.
   PubMed Web of Science ®Google Scholar
• van der Graaf A, Cuffie-Jackson C, Vissers MN, et al. Efficacy and safety of coadministration of ezetimibe and simvastatin in adolescents with heterozygous familial hypercholesterolemia. J Am Coll Cardiol. 2008;52(17):1421–1429.
   PubMed Web of Science ®Google Scholar
• Newman CB, Preiss D, Tobert JA, et al. Statin safety and associated adverse events: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2019;39(2):e38–e81.
   PubMed Web of Science ®Google Scholar
• Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375(9716):735–742.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195–2207.
   PubMed Web of Science ®Google Scholar
• Conte C, Rousseau V, Vert C, et al. Adverse drug reactions of statins in children and adolescents: a descriptive analysis from VigiBase, the WHO global database of individual case safety reports. Fundam Clin Pharmacol. 2020;34(4):518–520.
   PubMed Web of Science ®Google Scholar
• Daniels S, Caprio S, Chaudhari U, et al. PCSK9 inhibition with alirocumab in pediatric patients with heterozygous familial hypercholesterolemia: the ODYSSEY KIDS study. J Clin Lipidol. 2020;14(3):322–330. e5.
   PubMed Web of Science ®Google Scholar
• Chacra APM, Ferrari MC, Rocha VZ, et al. Case report: the efficacy and safety of lomitapide in a homozygous familial hypercholesterolemic child. J Clin Lipidol. 2019;13(3):397–401.
   PubMed Web of Science ®Google Scholar
• Tonstad S, Knudtzon J, Sivertsen M, et al. Efficacy and safety of cholestyramine therapy in peripubertal and prepubertal children with familial hypercholesterolemia. J Pediatr. 1996;129(1):42–49.
   PubMed Web of Science ®Google Scholar
• Perry CM. Colesevelam: in pediatric patients with heterozygous familial hypercholesterolemia. Paediatr Drugs. 2010;12(2):133–140.
   PubMedGoogle Scholar
• Kusters DM, Caceres M, Coll M, et al. Efficacy and safety of ezetimibe monotherapy in children with heterozygous familial or nonfamilial hypercholesterolemia. J Pediatr. 2015;166(6):1377–84 e1-3.
   PubMed Web of Science ®Google Scholar
• Ito MK, Santos RD. PCSK9 inhibition with monoclonal antibodies: modern management of hypercholesterolemia. J Clin Pharmacol. 2017;57(1):7–32.
   PubMed Web of Science ®Google Scholar
• Blom DJ, Harada-Shiba M, Rubba P, et al. Efficacy and safety of alirocumab in adults with homozygous familial hypercholesterolemia: the ODYSSEY HoFH trial. J Am Coll Cardiol. 2020;76(2):131–142.
   PubMed Web of Science ®Google Scholar
• Defesche JC, Stefanutti C, Langslet G, et al. Efficacy of alirocumab in 1191 patients with a wide spectrum of mutations in genes causative for familial hypercholesterolemia. J Clin Lipidol. 2017;11(6):1338–1346. e7.
   PubMed Web of Science ®Google Scholar
• Santos RD, Ruzza A, Hovingh GK, et al. Evolocumab in pediatric heterozygous familial hypercholesterolemia. N Engl J Med. 2020;383(14):1317–1327.
   PubMed Web of Science ®Google Scholar
• Raal FJ, Kallend D, Ray KK, et al. Inclisiran for the treatment of heterozygous familial hypercholesterolemia. N Engl J Med. 2020;382(16):1520–1530.
   PubMed Web of Science ®Google Scholar
• Goldberg AC, Leiter LA, Stroes ESG, et al. Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the clear wisdom randomized clinical trial. Jama. 2019;322(18):1780–1788.
   PubMed Web of Science ®Google Scholar
• Blom DJ, Raal FJ, Santos RD, et al. Lomitapide and mipomersen-inhibiting microsomal triglyceride transfer protein (MTP) and apoB100 synthesis. Curr Atheroscler Rep. 2019;21(12):48.
   PubMed Web of Science ®Google Scholar
• Raal FJ, Rosenson RS, Reeskamp LF, et al. Evinacumab for Homozygous familial hypercholesterolemia. N Engl J Med. 2020;383(8):711–720.
   PubMed Web of Science ®Google Scholar